Mitchell E. Levinson - 19 Aug 2021 Form 4 Insider Report for Pulse Biosciences, Inc. (PLSE)

Role: Chief Strategy Officer, Director
Signature: /s/ Sandra Gardiner, as Attorney-in-Fact
Issuer symbol: PLSE
Transactions as of: 19 Aug 2021
Net transactions value: $0
Form type: 4
Filing time: 20 Aug 2021, 16:22:05 UTC
Previous filing: 21 May 2021
Next filing: 24 Mar 2023
SEC: View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	PLSE	Stock Option (right to buy)	Award	$0	+65,510		$0.000000	65,510	19 Aug 2021	Common Stock	65,510	$21.12	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	50% of the shares subject to the option will vest in equal annual installments on the second, third and fourth anniversary of the grant date, and the other 50% of the shares subject to the option will vest upon the achievement of performance objectives established by the Compensation Committee of the Issuer, with vesting targets set at 25% (8,188 option shares) over the following four years on the anniversary of the grant date. All vesting is subject to the Reporting Person's continued service through each vesting date.

Content

50% of the shares subject to the option will vest in equal annual installments on the second, third and fourth anniversary of the grant date, and the other 50% of the shares subject to the option will vest upon the achievement of performance objectives established by the Compensation Committee of the Issuer, with vesting targets set at 25% (8,188 option shares) over the following four years on the anniversary of the grant date. All vesting is subject to the Reporting Person's continued service through each vesting date.